Laurie A. VanderVeen

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

Deborah H. Charych, Ute Hoch, John L. Langowski et al. · Clinical Cancer Research · 2016 · 385 citations

Induction of frameshift and base pair substitution mutations by the major DNA adduct of the endogenous carcinogen malondialdehyde

Laurie A. VanderVeen, Muhammed F. Hashim, Yu Shyr et al. · Proceedings of the National Academy of Sciences · 2003 · 117 citations · Full text

Genetics, Molecular Biology, Escherichia Coli +18

Evaluation of the Mutagenic Potential of the Principal DNA Adduct of Acrolein

Laurie A. VanderVeen, Muhammed F. Hashim, Lubomir V. Nechev et al. · Journal of Biological Chemistry · 2001 · 109 citations · Full text

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial

Samir K. Gupta, Mezgebe Berhe, Gordon Crofoot et al. · The Lancet HIV · 2022 · 96 citations

Treatment And Prevention, Initial Treatment, Clinical Trials +6

Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir

Nicolas Margot, Vidula Naik, Laurie A. VanderVeen et al. · The Journal of Infectious Diseases · 2022 · 53 citations